Donald E. Tsai

5.6k citations

117 papers · 3.3k indexed · h-index 32

Impact in

Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment
Oncology top 1%
- Viral-associated cancers and disorders
- Polyomavirus and related diseases
- CAR-T cell therapy research

Papers in

Genetics 33
- Chronic Lymphocytic Leukemia Research 28
Hematology 31
- Hematopoietic Stem Cell Transplantation 10
- Multiple Myeloma Research and Treatments 9

Co-authors: Edward A. Stadtmauer Stephen J. Schuster David Porter Alison W. Loren Jack D. Keene Robert M. Kotloff Sunita D. Nasta Selina M. Luger
Journals: Blood (18 papers)American Journal of Transplantation (6 papers)Journal of Clinical Oncology (6 papers)Bone Marrow Transplantation (6 papers)Medical Oncology (4 papers)
Partner nations: United States Australia Poland

In The Last Decade

Donald E. Tsai

113 papers receiving 3.2k citations

Peers

Countries citing papers authored by Donald E. Tsai

Since Specialization

Citations

This map shows the geographic impact of Donald E. Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald E. Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald E. Tsai more than expected).

Fields of papers citing papers by Donald E. Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald E. Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald E. Tsai. The network helps show where Donald E. Tsai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Donald E. Tsai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Donald E. Tsai Line = papers co-authored together Donald E. Tsai links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma PubMed ·Nikita Dave, 吴学安, A Watts, Shaoxiong Yao, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei‐Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta	2025	0
2	A comprehensive study of Z-DNA density and its evolutionary implications in birds BMC Genomics ·S. Kelly, Shang‐Hung Chang, Jinn-Jy Lin, Katharina Glock, Maíra Suzuka Kudo, Donald E. Tsai, 余翠萍, Chung‐Yu Lan, Chuang‐Rung Chang, Chih-Feng Chen, Chen Siang Ng	2024	3
3	Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol Blood Advances ·Sarah Nikiforow, Jennifer Whangbo, Ran Reshef, Donald E. Tsai, Nancy Bunin, Rolla Abu‐Arja, Kris M. Mahadeo, Wen‐Kai Weng, Koen van Besien, David M. Loeb, Sunita D. Nasta, Eneida R. Nemecek, Hans Michael Huck, Yan Sun, Jean N Labeque, Justin T. Wahlstrom, Aditi Mehta, Laurence Gamelin, Rajani Dinavahi, Susan E. Prockop	2024	8
4	Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial Blood ·Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj C. Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, Rikelmy Santos Sales, Sonya C. Chapman, Narasimha Marella, Samuel McNeely, Jennifer R. Brown	2024	11
5	CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies Clinical Lymphoma Myeloma & Leukemia ·Catherine E. Muehlenbein, Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah, Krish Patel, Kami J. Maddocks, Yucai Wang, Briza Pérez, Sarang Abhyankar, Donald E. Tsai, Toby A. Eyre	2023	1
6	MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment Clinical Lymphoma Myeloma & Leukemia ·Michael Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo Ma, Ian W. Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami J. Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Briza Pérez	2023	1
7	P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT HemaSphere ·Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo Ma, Ian W. Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami J. Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Briza Pérez, Michael Wang, Nirav N. Shah	2023	1
8	Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment. Journal of Clinical Oncology ·Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo Ma, Ian W. Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami J. Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Briza Pérez, Michael Wang	2023	1
9	Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder Biology of Blood and Marrow Transplantation ·Susan E. Prockop, Tsungying Yang, Robert A. Baiocchi, Nancy Bunin, Kris M. Mahadeo, Eneida R. Nemecek, Sarah Nikiforow, Ran Reshef, Donald E. Tsai, Willis H. Navarro, Richard J. O’Reilly	2018	6
10	The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder American Journal of Transplantation ·Marlise R. Luskin, Bjoern Winkler, Kay See Tan, Soo Jin Choi, Edward A. Stadtmauer, Stephen J. Schuster, David L. Porter, Robert H. Vonderheide, Adam Bagg, Daniel F. Heitjan, Donald E. Tsai, Ran Reshef	2015	118
11	Adjuvant Rituximab Therapy of Pemphigus Archives of Dermatology ·Luisa Lunardon, Ta-Tung Wei, Kathleen J. Propert, Nicole Fett, John R. Stanley, Victoria P. Werth, Donald E. Tsai, Aimee Payne	2012	83
12	A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia Clinical Cancer Research ·Donald E. Tsai, Selina M. Luger, Charalambos Andreadis, Dan T. Vogl, Narcisa Naomi Chang-López, 民恵熊倉, Ami Goradia, Alison W. Loren, Alexander E. Perl, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, James E. Thompson, Cezary Swider, Adam Bagg, Anthony R. Mato, Martin Carroll	2008	29
13	A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein–Barr virus Virology ·Jason S. Knight, Ke Lan, Bharat Bajaj, Nikhil Sharma, Donald E. Tsai, Erle S. Robertson	2006	6
14	Primary lymphomas of the cervix and uterus: The University of Pennsylvania's experience and a review of the literature Leukemia & lymphoma ·Noelle V. Frey, Jakub Svoboda, Charalambos Andreadis, Donald E. Tsai, Stephen J. Schuster, Rebecca Elstrom, Stephen C. Rubin, Sunita D. Nasta	2006	52
15	Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-Occlusive Disease after Stem Cell Transplantation Journal of Hematotherapy & Stem Cell Research ·John F. Gerecitano, Clarissa Mathias, Rosemarie Mick, Kathleen M. Duffy, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster, Donald E. Tsai, Sunita D. Nasta, Jesse A. Berlin, Bahattin Tunç, Katherine A. High, David L. Porter	2003	4
16	Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma Arthritis Care & Research ·Bradley G. Somer, Donald E. Tsai, Lisa Downs, Mohamad Nasir Shafiee, Stephen J. Schuster	2003	58
17	Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90–Labeled Anti-CD22 Monoclonal Antibody Clinical Lymphoma ·Donald E. Tsai, Ivan Maillard, Stephen J. Schuster, Sunita D. Nasta, David L. Porter, Thomas R. Klumpp, David M. Goldenberg, Selina M. Luger, Abass Alavi, Robert M. Sharkey, Amani Ouedrani, Edward A. Stadtmauer	2003	7
18	Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy Annals of Hematology ·Ronald J. Buckanovich, Felix Owusu, Carrie Tompkins Stricker, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster, Kathleen M. Duffy, Donald E. Tsai, Amy A. Pruitt, David L. Porter	2002	43
19	Expression of SHP-1 Phosphatase Indicates Post-Germinal Center Cell Derivation of B-Cell Posttransplant Lymphoproliferative Disorders Laboratory Investigation ·Michele Paessler, Plamen Kossev, Donald E. Tsai, Kenny Garcia, Mirosław Majewski, Qian Zhang, Preetha Ramalingam, Stephen J. Schuster, John Tomaszewski, Daniel A. Arber, Eric D. Hsi, Mariusz A. Wasik	2002	13
20	U1-snRNP-A protein selects a ten nucleotide consensus sequence from a degenerate RNA pool presented in various structural contexts Nucleic Acids Research ·Donald E. Tsai, Nesrin Yatman, Jack D. Keene	1991	126

About Donald E. Tsai

Donald E. Tsai is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Oncology and Transplantation, having authored 117 papers that have together received 3.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (45 papers), Viral-associated cancers and disorders (42 papers), Chronic Lymphocytic Leukemia Research (28 papers), Polyomavirus and related diseases (25 papers), CNS Lymphoma Diagnosis and Treatment (10 papers), Hematopoietic Stem Cell Transplantation (10 papers), Multiple Myeloma Research and Treatments (9 papers) and Transplantation: Methods and Outcomes (8 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.2k citations), Oncology (1.8k citations), Hematology (537 citations), Transplantation (120 citations) and Genetics (435 citations). Donald E. Tsai has collaborated with scholars based in United States, Australia and Poland. Frequent co-authors include Edward A. Stadtmauer, Stephen J. Schuster, David Porter, Alison W. Loren, Jack D. Keene, Robert M. Kotloff, Sunita D. Nasta, Selina M. Luger, Jakub Svoboda and Bradley G. Somer. Their work appears in journals such as Blood, American Journal of Transplantation, Journal of Clinical Oncology, Bone Marrow Transplantation and Medical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact